|
A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT. |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Health Advances; Inovio Pharmaceuticals; Merck; Oncogenex; Pieris Pharmaceuticals |
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Principa Biopharma (Inst) |
|
|
Consulting or Advisory Role - Altor BioScience; BioCancell; MDxHealth |
|
|
|
Research Funding - Genentech |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Tolmar |
Speakers' Bureau - Bayer; Dendreon; Janssen |
|
|
Consulting or Advisory Role - MDxHealth |
Research Funding - FKD Therapies (Inst); Genomic Health (Inst); Photocure (Inst); Roche/Genentech (Inst) |
|
|
Honoraria - Baxter; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; MDxHealth; Merck; Photocure; Roche/Genentech; Taris Biomedical; Telesta Therapeutics |
Consulting or Advisory Role - Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; MDxHealth; Merck; Natera; photocure; Roche/Genentech; Taris BioMedical |
|
|
Honoraria - Bayer Schering Pharma; Janssen-Cilag |
Consulting or Advisory Role - Bayer Schering Pharma; Janssen-Cilag |
|
|
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Janssen; Lilly; MSD |
Speakers' Bureau - Chugai Pharma; MSD |
Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst); Takeda (Inst) |
|
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Ferring |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Millennium; Takeda |
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb |
Other Relationship - Agios |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BioCancell; Bristol-Myers Squibb; Cepheid; Nucleix; Spectrum Pharmaceuticals; taris; Tocagen |
Research Funding - cepheid (Inst); Nucleix (Inst); taris (Inst) |